FDA approves new breast cancer treatment

fda breast cancer treatment verzenio

On Sept. 28, the U.S. Food and Drug Administration (FDA) approved Verzenio (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that has progressed after endocrine therapy.Read more via FDA.gov.


Please enter your comment!
Please enter your name here